Who is sponsoring NCT04461847?

NCT04461847 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT04461847?

Interventions in NCT04461847: subcutaneous mastectomy, endoscopic subcutaneous mastectomy.

What condition does NCT04461847 study?

NCT04461847 studies Endoscopic Subcutaneous Mastectomy.

Is NCT04461847 still recruiting?

NCT04461847 is currently status unknown. Last updated 1 December 2020.

Last reviewed 2020-12-01 · How we verify

NCT04461847

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ESM Versus OM ：A Randomized Controlled Trial

Status unknown NA Last updated 1 December 2020

What this trial tests

NA trial testing subcutaneous mastectomy in Endoscopic Subcutaneous Mastectomy in 287 participants. Status unknown.

Timeline

1 December 2020

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Beijing Friendship Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	287
Start date	1 December 2020
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

subcutaneous mastectomy
endoscopic subcutaneous mastectomy

Conditions studied

Endoscopic Subcutaneous Mastectomy — all drugs for Endoscopic Subcutaneous Mastectomy →

Sponsor

Beijing Friendship Hospital

Who can join

Adults 18 to 70, female only, with Endoscopic Subcutaneous Mastectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The consideration of quality of life issues has led to the development of alternative surgeries for breast cancer patients, particularly in the case of localized disease. Nipple-sparing subcutaneous mastectomy (SM), for example, was designed to preserve the nipple-areola complex which facilitates breast reconstruction. However, SM still leaves behind a conspicuous scar.There have already been some observation study show that endoscopic subcutaneous mastectomy(ESM) can improve the cosmesis outcomes and at the same time as safe as the traditional SM.However there is no RCT in this field.That is why the investigators design this study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Single-port insufflation endoscopic nipple-sparing mastectomy in early breast cancer: a retrospective cohort study.
Liu WH, Wu SS, Tian YM, Liu J, et al · · 2023 · cited 4× · PMID 38021192 · DOI 10.21037/gs-23-148
Oncological outcome of single-port insufflation endoscopic nipple-sparing mastectomy versus open mastectomy in early breast cancer patients: a study protocol for a randomised controlled trial.
Wang ZH, Ding G, Wu S, Song JN, et al · · 2022 · cited 1× · PMID 35501091 · DOI 10.1136/bmjopen-2020-047866

Verify or expand the search:

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04461847 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 1 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04461847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing